Dihydrotachysterol is a synthetic analog of vitamin D that does not require renal activation like vitamin D2 or Vitamin D3.
- Generic Name
- DrugBank Accession Number
A vitamin D that can be regarded as a reduction product of vitamin D2.
- Small Molecule
- Average: 398.6642
- Chemical Formula
- Anti-tetany substance 10
Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.
- Associated Conditions
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
Dihydrotachysterol is hydroxylated in the liver to 25-hydroxydihydrotachysterol, which is the major circulating active form of the drug. It does not undergo further hydroxylation by the kidney and therefore is the analogue of 1, 25-dihydroxyvitamin D. Dihydrotachysterol is effective in the elevation of serum calcium by stimulating intestinal calcium absorption and mobilizing bone calcium in the absence of parathyroid hormone and of functioning renal tissue. Dihydrotachysterol also increases renal phosphate excretion.
- Mechanism of action
Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor)stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone.
Target Actions Organism AVitamin D3 receptoragonist Humans
- Volume of distribution
- Protein binding
- Not Available
- Route of elimination
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
Toxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D.
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Acetyldigitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Acetyldigitoxin. Alfacalcidol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Alfacalcidol. Aluminum hydroxide The serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol. Beclomethasone dipropionate The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Beclomethasone dipropionate. Bendroflumethiazide The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Dihydrotachysterol. Benzthiazide The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Dihydrotachysterol. Betamethasone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Betamethasone. Betamethasone phosphate The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Betamethasone phosphate. Budesonide The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Budesonide. Calcifediol The risk or severity of adverse effects can be increased when Calcifediol is combined with Dihydrotachysterol.Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more
- Food Interactions
- No interactions found.
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- AT 10 / Atiten (Bayer) / Dihydral (Solvay) / Dygratyl (Dishman) / Tachystin (Chauvin)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Hytakerol Capsule .125 mg Oral Sanofi Synthelabo 1952-12-31 2003-07-30
- ATC Codes
- A11CC02 — Dihydrotachysterol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Steroids and steroid derivatives
- Sub Class
- Vitamin D and derivatives
- Direct Parent
- Vitamin D and derivatives
- Alternative Parents
- Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
- Alcohol / Aliphatic homopolycyclic compound / Cyclic alcohol / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Secondary alcohol / Triterpenoid
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- hydroxy seco-steroid, seco-ergostane, vitamin D (CHEBI:4591) / Vitamin D2 and derivatives (LMST03010056)
- Affected organisms
- Humans and other mammals
- CAS number
- InChI Key
- IUPAC Name
- Synthesis Reference
von Werder, F.; U.S. Patent 2,228,491; January 14,1941; assigned to Winthrop Chemical Company, Inc.
- General References
- DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. [Article]
- Bosch R, Thijssen JH, Duursma SA: Action and metabolism of dihydrotachysterol2. J Steroid Biochem. 1987;27(4-6):829-36. [Article]
- Pierides AM: Pharmacology and therapeutic use of vitamin D and its analogues. Drugs. 1981 Apr;21(4):241-56. [Article]
- Gagnon R, Ogden GW, Just G, Kaye M: Comparison of dihydrotachysterol and 5,6-trans vitamin D3 on intestinal calcium absorption in patients with chronic renal failure. Can J Physiol Pharmacol. 1974 Apr;52(2):272-4. [Article]
- Codifa: Atiten (dihydrotachisterol) oral drops [Link]
- Human Metabolome Database
- KEGG Drug
- KEGG Compound
- PubChem Compound
- PubChem Substance
- Therapeutic Targets Database
- RxList Drug Page
- Drugs.com Drug Page
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Advanced Malignant Glioma 1 2 Completed Treatment Advanced Renal Cell Carcinoma (aRCC) 1 2 Withdrawn Treatment Parkinson's Disease (PD) 1 1 Completed Not Available Healthy Subjects (HS) 2 1 Completed Basic Science Poliomyelitis / Tropical Enteropathy 1 Not Available Completed Prevention Follicular Tonsillitis (Chronic) 1 Not Available Completed Treatment Thrombotic events 1 Not Available Recruiting Treatment Ectasia / Keratoconus 1
- Not Available
- Murfreesboro Pharmaceutical Nursing Supply
- Professional Co.
- Sanofi-Aventis Inc.
- Dosage Forms
Form Route Strength Capsule Oral 0.5 mg Solution Oral 1 mg/mL Solution / drops Oral 1 MG/ML Capsule Oral .125 mg
Unit description Cost Unit Dihydrotachysterol powder 15.56USD gDrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
- Not Available
- Experimental Properties
Property Value Source logP 7.5 Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000125 mg/mL ALOGPS logP 7.86 ALOGPS logP 7.4 ChemAxon logS -6.5 ALOGPS pKa (Strongest Acidic) 18.3 ChemAxon pKa (Strongest Basic) -1.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 20.23 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 129.11 m3·mol-1 ChemAxon Polarizability 51.76 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon
- Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9443 Caco-2 permeable + 0.822 P-glycoprotein substrate Substrate 0.6576 P-glycoprotein inhibitor I Inhibitor 0.6558 P-glycoprotein inhibitor II Non-inhibitor 0.8328 Renal organic cation transporter Non-inhibitor 0.8051 CYP450 2C9 substrate Non-substrate 0.817 CYP450 2D6 substrate Non-substrate 0.8853 CYP450 3A4 substrate Substrate 0.7432 CYP450 1A2 substrate Non-inhibitor 0.908 CYP450 2C9 inhibitor Non-inhibitor 0.9053 CYP450 2D6 inhibitor Non-inhibitor 0.9546 CYP450 2C19 inhibitor Non-inhibitor 0.9027 CYP450 3A4 inhibitor Non-inhibitor 0.8342 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7962 Ames test Non AMES toxic 0.9236 Carcinogenicity Non-carcinogens 0.9223 Biodegradation Not ready biodegradable 0.9623 Rat acute toxicity 3.1244 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8502 hERG inhibition (predictor II) Non-inhibitor 0.708
- Mass Spec (NIST)
- Not Available
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
- Pharmacological action
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
- Gene Name
- Uniprot ID
- Uniprot Name
- Vitamin D3 receptor
- Molecular Weight
- 48288.64 Da
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Qaw F, Calverley MJ, Schroeder NJ, Trafford DJ, Makin HL, Jones G: In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92. [Article]
- Qaw FS, Makin HL, Jones G: Metabolism of 25-hydroxydihydrotachysterol3 in bone cells in vitro. Steroids. 1992 May;57(5):236-43. [Article]
- Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. doi: 10.1210/jc.2010-0918. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2021 10:52